Neumora Therapeutics (NASDAQ:NMRA) Insider Sells $102,288.91 in Stock

Neumora Therapeutics, Inc. (NASDAQ:NMRA) insider Daljit Singh Aurora sold 67,741 shares of the company’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $1.51, for a total value of $102,288.91. Following the transaction, the insider directly owned 48,750 shares in the company, valued at approximately $73,612.50. This represents a 58.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Daljit Singh Aurora also recently made the following trade(s):

• On Thursday, August 20th, Daljit Singh Aurora sold 66,711 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.51, for a total transaction of $100,733.61.
• On Friday, August 21st, Daljit Singh Aurora sold 21,055 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.60, for a total value of $33,688.00.
• On Friday, August 21st, Daljit Singh Aurora sold 20,553 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.59, for a total transaction of $32,679.27.
• On Wednesday, August 19th, Daljit Singh Aurora sold 30,918 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.65, for a total transaction of $51,014.70.
• On Wednesday, August 19th, Daljit Singh Aurora sold 31,000 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.65, for a total value of $51,150.00.
• On Monday, August 17th, Daljit Singh Aurora sold 55,016 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.50, for a total transaction of $82,524.00.
• On Monday, August 17th, Daljit Singh Aurora sold 91,690 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.50, for a total transaction of $137,535.00.
• On Tuesday, August 18th, Daljit Singh Aurora sold 34,987 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.59, for a total transaction of $55,629.33.
• On Tuesday, August 18th, Daljit Singh Aurora sold 34,162 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.58, for a total transaction of $53,975.96.

Neumora Therapeutics Stock Up 7.6%

Shares of NMRA traded up $0.12 during mid-day trading on Friday, reaching $1.63. 498,604 shares of the company were exchanged, compared to its average volume of 765,644. The business has a 50 day simple moving average of $1.60 and a two-hundred day simple moving average of $2.10. The company has a debt-to-equity ratio of 1.19, a current ratio of 4.50 and a quick ratio of 5.09. Neumora Therapeutics, Inc. has a 52 week low of $0.83 and a 52 week high of $3.65.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01. As a group, research analysts forecast that Neumora Therapeutics, Inc. will post -0.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Mizuho reduced their price objective on shares of Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a research note on Thursday, June 18th. Wall Street Zen upgraded shares of Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Royal Bank Of Canada decreased their price objective on shares of Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a report on Monday, July 13th. HC Wainwright restated a “buy” rating on shares of Neumora Therapeutics in a report on Tuesday, July 28th. Finally, Weiss Ratings downgraded shares of Neumora Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $6.57.

Institutional Investors Weigh In On Neumora Therapeutics

Institutional investors have recently modified their holdings of the stock. HBK Sorce Advisory LLC bought a new stake in Neumora Therapeutics during the 2nd quarter valued at $26,000. Hsbc Holdings PLC purchased a new stake in Neumora Therapeutics in the fourth quarter valued at approximately $27,000. Virtu Financial LLC purchased a new position in shares of Neumora Therapeutics during the 3rd quarter valued at about $31,000. Fred Alger Management LLC acquired a new position in Neumora Therapeutics in the fourth quarter valued at approximately $40,000. Finally, Canada Pension Plan Investment Board acquired a new stake in Neumora Therapeutics during the second quarter valued at $41,000. 47.65% of the stock is owned by institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.